Kandil M, Jaber S, Desai D, et al. - In adults with migraine, researchers conducted a prospective, randomized, double-blind trial investigating the efficacy of magnesium vs conventional treatments to improve patient outcomes and ED workflow. They randomized adults who presented to the ED with a diagnosis of migraine to receive intravenous magnesium, prochlorperazine, or metoclopramide, with 61 patients receiving magnesium, 52 receiving prochlorperazine, and 44 receiving metoclopramide. At 30 minutes after initiation of infusion of study drug, they assessed change in pain from baseline on a numeric rating scale. The outcomes suggest no significant difference in numeric rating scale at 30 minutes between magnesium, metoclopramide and prochlorperazine. The three groups showed no statistically significant differences in ED length of stay, rescue analgesia, or adverse effects. Dizziness, anxiety, and akathisia were the reported adverse effects.